Sobered by mount­ing costs, Dy­navax looks to un­load I/O, slash jobs and cir­cle wag­ons around Hep­lisav

Hep B vac­cine mak­er Dy­navax has re­al­ized it needs por­tion con­trol be­cause there’s far too much on its plate.

On Thurs­day, the Cal­i­for­nia-based com­pa­ny said it need­ed to fo­cus all its re­sources on its 2017-ap­proved Hep­lisav-B and its broad­er vac­cine busi­ness, so it is ex­plor­ing strate­gic al­ter­na­tives for its im­muno-on­col­o­gy pro­grams and cut­ting jobs.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER